Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma.

J Invest Dermatol · 2015 · PMC4567913 · PMID 26016894

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Comparing Plk1 levels of 6 NRAS(Q61) with 4 NRAS(G12) mutant melanoma cell lines also showed a trend towards higher Plk1 mRNA and protein expression in NRAS(Q61) cells; however, these analyses were not statistically significant (p=0.08; p=0.052; Fig.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.